GSK 1034702
Cognitive Disorder
GlaxoSmithKlineSmall moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
150 Active assets in the Cognitive Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nicotine University of Southern California | Phase 2 | BBB |
Oxybutynin University of Alberta | Phase 4 | BBB |
Rivastigmine VA Office of Research and Development | Phase 4 | BB |
Metformin Fudan University | Phase 4 | BB |
LEVODOPA Vanderbilt University Medical Center | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →